Eastern Equine Encephalitis

Etiology

Eastern equine encephalitis virus (EEEV), the causative agent, is a single-stranded RNA arbovirus belonging to the Togaviridae family, genus Alphavirus. The virus persists in nature through an enzootic cycle involving passerine birds and its primary vector, Culiseta melanura mosquitoes, which typically inhabit freshwater hardwood swamps. Recent evidence indicates that additional mosquito species, including Coquillettidia perturbans, Aedes cinereus, and Aedes canadensis, contribute to EEEV transmission.[4]

Mosquitoes acquire the virus during blood meals from passerine birds and, in turn, may incidentally transmit it to a range of vertebrate hosts, including mammals, reptiles, and amphibians. Occasionally, the virus extends beyond this enzootic cycle to infect dead-end hosts, eg, humans, swine, equids, and pheasants. Humans qualify as dead-end hosts because viremia levels remain too low to sustain transmission back to mosquitoes. Cross-species transmission occurs sporadically, with climatic changes and global warming likely contributing to the rising incidence of cases. Other factors influencing transmission dynamics include environmental disturbances, migratory bird patterns, and human activities that increase exposure to vector habitats.[5] In 2017, EEEV transmission was documented for the first time via organ transplantation.[6][7]

Epidemiology

The first recognized human cases of EEEV occurred during a Massachusetts outbreak in 1938. Since then, infections have been reported sporadically along the Atlantic and Gulf coasts, where ecological conditions support enzootic transmission. A landmark outbreak in 1959 in New Jersey produced 32 cases within 8 weeks, while in 2019, 38 cases marked the highest annual incidence in the past 2 decades.[CDC. Eastern Equine Encephalitis, Historical Data. June 3, 2025] 

Since 2003, EEE has been a nationally notifiable disease and is monitored through ArboNET, the national arboviral surveillance system. To date, cases have been documented in 20 states, with Massachusetts, Florida, Michigan, and New Hampshire reporting the highest numbers nationwide. The annual mean incidence is approximately 11 cases, with neuroinvasive disease occurring twice as often in males. Incidence exhibits a bimodal distribution, with the highest risk observed among children younger than 5, adults older than 60, and immunocompromised individuals.[8]

Additional high-risk groups include those living in or visiting endemic forested areas near swamps or marshes, and individuals with outdoor occupational (eg, agriculture) or recreational (eg, camping and gardening) exposures.[9] Recent data indicate that the case-fatality rate for EEEV ranges between 30% and 40%, with nearly half of survivors experiencing long-term neurologic sequelae. Notably, ArboNET data reveal substantially more non-human than human activity, likely reflecting ecological barriers to EEEV spillover from enzootic to epizootic cycles, as well as limitations in surveillance and diagnostic testing.[10]

Pathophysiology

Following the bite of an infected mosquito, EEEV enters the skin and targets dendritic and Langerhans cells. These antigen-presenting cells migrate to regional lymphoid tissue, promoting viral replication and subsequent viremia. The virus then spreads systemically and invades the central nervous system through the bloodstream or peripheral nerves. Within the central nervous system, EEEV triggers a pronounced neuroinflammatory response characterized by activation of microglia and astrocytes, release of proinflammatory cytokines, eg, IL-6 and TNF-α, disruption of blood–brain barrier integrity, and widespread neuronal injury. The incubation period typically spans 4 to 10 days before clinical symptoms manifest.[11][5]

Histopathology

Experimental and clinical studies have demonstrated the mesenchymal cell tropism of EEEV, with early viral replication documented in bone, tendon, and myocardial tissue. In addition, involvement of the lungs, stomach, kidneys, and spleen has been reported in systemic infection.[6] Neuropathologic findings are generally nonspecific and overlap with other viral encephalitides, most commonly showing perivascular lymphohistiocytic cuffing. Additional features may include leptomeningeal vascular congestion, hemorrhage, encephalomalacia, and, in rare instances, pyogenic meningeal exudates.[12][13]

Detection of viral antigen within affected tissues can be achieved by immunohistochemical staining.[14] A case report from Duke University described optic nerve pathology mirroring cerebral changes in a fatal human infection.[12] Some authors have also reported focal infiltration of neutrophils and macrophages in the brain parenchyma, leading to neuronal destruction, focal necrosis, and local demyelination with the formation of glial nodules. In patients who succumbed later in the disease course, cortical atrophy has been documented at autopsy.[13] 

History and Physical

Symptomatic arboviral infections in humans can be broadly categorized into 3 clinical syndromes: febrile systemic illness, exemplified by uncomplicated dengue fever; hemorrhagic fever, as seen in dengue hemorrhagic fever and yellow fever; and encephalitis, which encompasses EEE, Venezuelan equine encephalitis, Japanese encephalitis, and La Crosse encephalitis. Approximately 96% of individuals infected with EEEV remain asymptomatic.

Among those who develop illness, the initial presentation is typically nonspecific, characterized by fever, headache, malaise, chills, arthralgias, nausea, and vomiting.[5] Fewer than 5% of infected individuals progress to meningitis or encephalitis. Neurologic symptoms usually emerge within the first 5 days and are clinically indistinguishable from other viral encephalitides. Altered mental status and seizures are the most frequent findings, although paresthesias and focal weakness have also been reported.[5][13] 

Several studies have highlighted the prognostic value of the prodromal phase. A brief prodrome is associated with higher rates of mortality or severe neurologic sequelae, whereas a more prolonged, mild-to-moderate prodrome is more often linked to survival with moderate disability or full recovery, particularly in pediatric patients.[5] Risk factors for poor neurologic outcomes include hyponatremia, diffuse and symmetric abnormalities on neuroimaging, severe functional impairment at presentation, markedly depressed brain activity on electroencephalography, and underlying immunosuppression.[9]

Evaluation

Basic laboratory findings in EEE may include peripheral leukocytosis. Cerebrospinal fluid (CSF) analysis typically demonstrates pleocytosis that is initially neutrophilic and later transitions to a lymphocytic predominance, accompanied by elevated protein and normal glucose concentrations.[9][6] Specific diagnostic assays, including polymerase chain reaction (PCR) of blood or CSF and serologic testing, may have a negative result early in the illness but often become positive within the first week, when neurologic injury has already occurred.[5] Current recommendations emphasize obtaining repeated serum samples in patients with encephalitis and a high index of suspicion for viral etiology, since antibody titers can rise 4-fold within several days.

Moreover, a positive serum antibody result should not be disregarded in the setting of negative CSF nucleic acid testing, particularly early in the disease course. When a lumbar puncture cannot be repeated, serial serologic testing may support a definitive diagnosis.[15] Additionally, both antibody- and nucleic acid–based methods are valuable, although molecular testing may be particularly useful in immunocompromised patients with impaired antibody production.[8] Available modalities include enzyme-linked immunosorbent assay (ELISA) and indirect fluorescent antibody (IFA) testing.[16]

Neuroimaging findings typically involve the basal ganglia, thalami, and cerebral cortex. Magnetic resonance imaging (MRI), particularly T2-weighted and FLAIR sequences, often demonstrates focal lesions without marked edema, a contrast to common autopsy findings of severe cerebral edema that peak around day 12 in up to 60% of fatal cases. In pediatric patients, cortical involvement appears to predominate.[13] Early thalamic and basal ganglia involvement on MRI can help distinguish EEE from herpes simplex encephalitis.[13] Computed tomography (CT) may also reveal basal ganglia abnormalities, but MRI is considered more sensitive for detecting characteristic changes.[13] 

Treatment / Management

At present, no antiviral therapy has demonstrated efficacy in the management of EEE. Supportive care remains the cornerstone of treatment, often necessitating intensive care unit admission with ventilatory support.[5] Patient isolation is not required. In individuals with progressive encephalitis, routine monitoring of intracranial pressure and institution of pressure-directed therapies may be indicated. Decompressive craniotomy has been described in refractory cases. Anecdotal reports suggest poorer outcomes with corticosteroid use, whereas limited case reports have indicated possible benefit from immunoglobulin therapy.[17]

Because no licensed vaccine is available for human use, prevention is the primary strategy for controlling this infection. Public health measures focus on vector control through reduction of mosquito breeding sites and application of insecticides. At the individual level, personal protective behaviors—including the use of insect repellents and protective clothing—remain essential to minimize risk of exposure.

Differential Diagnosis

In regions where EEEV transmission is known to occur, clinicians should maintain a high index of suspicion for EEE in any patient presenting with aseptic meningitis or encephalitis. Additionally, all suspected cases should be promptly reported to the local health department for public health surveillance and response. The differential diagnosis for EEE includes a broad range of viral encephalitides, particularly herpes simplex virus, varicella-zoster virus, enteroviruses (eg, echoviruses), measles, mumps, and arboviruses, eg, West Nile virus or Japanese encephalitis virus. In rare instances, nonviral etiologies, eg, prion disease, including Creutzfeldt–Jakob disease, may also be considered in the differential.[13]

Pertinent Studies and Ongoing Trials

Currently, licensed vaccines against EEEV are available only for veterinary use in horses, with no human vaccine. An inactivated EEEV vaccine has been administered under Investigational New Drug protocols to protect laboratory workers, but it remains unavailable commercially. More recently, a trivalent Modified Vaccinia Ankara (MVA-BN WEV) vaccine targeting EEEV, VEEV, and WEEV demonstrated safety and immunogenicity in phase 1 trials and has progressed to phase 2.[18] Preclinical MVA-based constructs have also provided complete protection against lethal EEEV challenge in animal models.[19]

Prognosis

Eastern equine encephalitis carries a case-fatality rate as high as 41%, with most deaths occurring within the first 2 to 10 days of illness.[CDC.Clinical Signs and Symptoms of Eastern Equine Encephalitis.May 15, 2024] Among survivors, approximately half develop long-term neurologic sequelae, including epilepsy, motor deficits, cognitive impairment, and behavioral disturbances. Recent reports suggest that severe hyponatremia, marked cerebrospinal fluid pleocytosis, and depressed electroencephalogram activity are poor prognostic indicators, likely reflecting heightened neuroinflammation.[11] Corticosteroid therapy has been associated with worse neurologic outcomes, while anecdotal use of intravenous immunoglobulin has been reported, though evidence remains limited.[11] Overall, long-term disability is common, highlighting the importance of supportive management and preventive strategies.

Complications

Complications most frequently involve the central nervous system, resulting in lasting cognitive, motor, or sensory deficits. Among survivors, seizures are the most common sequelae, reported in up to 63% of cases, followed by paralysis, intellectual disability, and behavioral disturbances.[20][21] Psychiatric manifestations, including psychosis, have also been described.[22] In severe presentations, delayed recognition and intervention can contribute to autonomic instability, multiorgan failure, and ultimately death. Rare systemic complications have been reported, eg, hemophagocytic lymphohistiocytosis in a 5-month-old infant.[23]